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Abstract
Purpose—We examined in a prospective, randomized, international clinical trial the
performance of a previously defined 30-gene predictor (DLDA-30) of pathologic complete
response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin,
cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased
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sensitivity to FAC-only chemotherapy. We compared the pCR rates after T/FAC versus FAC×6
preoperative chemotherapy. We also performed an exploratory analysis to identify novel candidate
genes that differentially predict response in the two treatment arms.
Experimental Design—273 patients were randomly assigned to receive either weekly
paclitaxel × 12 followed by FAC × 4 (T/FAC, n=138), or FAC × 6 (n=135) neoadjuvant
chemotherapy. All patients underwent a pretreatment FNA biopsy of the tumor for gene
expression profiling and treatment response prediction.
Results—The pCR rates were 19% and 9% in the T/FAC and FAC arms, respectively (p<0.05).
In the T/FAC arm, the positive predictive value (PPV) of the genomic predictor was 38% (95%CI:
21–56%), the negative predictive value (NPV) 88% (CI:77–95%) and the AUC 0.711. In the FAC
arm, the PPV was 9% (CI:1–29%) and the AUC 0.584. This suggests that the genomic predictor
may have regimen-specificity. Its performance was similar to a clinical variable-based predictor
nomogram.
Conclusions—Gene expression profiling for prospective response prediction was feasible in
this international trial. The 30-gene predictor can identify patients with greater than average
sensitivity to T/FAC chemotherapy. However, it captured molecular equivalents of clinical
phenotype. Next generation predictive markers will need to be developed separately for different
molecular subsets of breast cancers.
INTRODUCTION
There are several clinical and molecular features that can identify generally more or less
chemotherapy sensitive subsets of breast cancers but there are no clinically useful predictive
biomarkers to select one chemotherapy regimen over another. Preoperative (neoadjuvant)
chemotherapy provides a direct opportunity to assess treatment sensitivity in early stage
breast cancers and pathologic complete response (pCR) is a powerful early surrogate of
long-term survival (1,2). Recent studies have established that basal-like or triple receptor-
negative breast cancers include a greater proportion of highly chemotherapy sensitive
tumors, reflected by the significantly higher pCR rates, compared to ER-positive breast
cancers (3,4). Among the ER-positive cancers, high Oncotype DX recurrence score
(Genomic Health Inc, Redwood City, CA), Luminal-B molecular class, HER-2
overexpression and high histologic or genomic grade are associated with greater
chemotherapy sensitivity (5,6,7). However, these molecular and clinicopathologic variables
appear to predict general chemotherapy sensitivity, and have limited value in guiding the
choice of a specific treatment regimen. Among several other markers, high expression/
amplification of Topoisomerase II alpha and low expression of microtubule binding protein
Tau have recently been suggested as potential predictors of sensitivity to anthracyclines and
taxanes, respectively (8,9). However, neither these nor other proposed markers showed
consistent clinically useful predictive value (10,11,12).
We previously developed a genomic predictor of pathologic complete response to
preoperative sequential weekly paclitaxel followed by fluorouracil, doxorubicin and
cyclophosphamide (T/FAC) chemotherapy from a single-arm retrospective study that
included 82 patients in the discovery and 51 in the validation phase (13). The genomic
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predictor uses information from 30 different probe sets (i.e. genes) and employs diagonal
linear discriminant analysis for prediction rules and is therefore referred to as the DLDA-30
predictor. The goal of the current study was to evaluate the predictive performance and
assess the regimen specificity of this multi-gene predictor in a prospective, two-arm,
randomized, multi-center, international, neoadjuvant clinical trial. Two commonly used,
standard chemotherapy regimens including T/FAC and FAC-alone were compared for pCR
rates. The predictive performance of the genomic signature was assessed independently in
each treatment arm and a marker-treatment-outcome interaction test was performed. We also
examined the performance of our previously reported clinical-pathologic variable-based
nomogram to predict pCR (14). It remains unknown if the sequential paclitaxel/FAC
regimen are superior to 6 courses of FAC or FEC (the control arm of this study) in terms of
pathologic response rates or survival. Therefore, we also compared the pCR rates for
patients who received T/FAC versus FAC×6 preoperative chemotherapy in this trial.
MATERIALS AND METHODS
Patient eligibility
Patients with clinical stage I–III breast cancer were eligible. Histological diagnosis of
invasive cancer and estrogen, progesterone and HER-2 receptor status were determined from
a diagnostic core needle or incisional biopsy before therapy. All patients had to agree to a
separate, pre-treatment research fine needle aspiration (FNA) of the cancer for gene
expression analysis. Patients were accrued at six international sites including The University
of Texas M. D. Anderson Cancer Center (MDACC, n=96) and the Lyndon B Johnson
General Hospital (LBJ, n=19) in Houston, TX, USA; the Instituto Nacional de
Enfermedades Neoplasicas in Lima, Peru (n=79); the Centro Medico Nacional de Occidente
in Guadalajara, Mexico (n=19); and the clinical trial group Grupo Español de Investigacion
en Cancer de Mama (GEICAM) in Spain (n=60). This study was approved by the
institutional review boards of each participating institution and all patients signed an
informed consent for voluntary participation. The study was conducted between October
2003 and October 2006.
Treatment
Treatment was not selected based on gene expression results, patients were centrally
randomized with blocked randomization at MDACC into one of two treatment arms; Arm
A: (T/FAC) weekly paclitaxel 80 mg/m2/week × 12 courses followed by 5-fluorouracil 500
mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 all on day 1 repeated in
21-day cycles × 4 courses. Epirubicin (100 mg/m2) could be substituted for doxorubicin at
the discretion of local investigators; Arm B: FAC (or FEC if epirubicin was used) × 6
courses at the same doses and schedule as above. Toxicity information was not collected
during this trial because the two treatment arms were considered standard community-based
therapy. Any patient developing unacceptable grade 3 or grade 4 toxicity was removed from
the study. Patients with clinical or radiological disease progression were considered as
having residual disease (RD) in the final analysis. After completion of neoadjuvant
chemotherapy, all patients underwent modified radical mastectomy or lumpectomy and
sentinel lymph node biopsy or axillary node dissection as determined by the surgeon; pCR
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was defined as the complete absence of invasive cancer cells in the breast and lymph nodes
(15). Pathologic response was centrally reviewed by a breast pathologist (WFS).
Gene expression analysis and response prediction
Two to three FNA passes obtained with 23- or 25-gauge needles were collected into vials
containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at 4°C until mailed to
MDACC in a cooler pack or dry ice. At MDACC, specimens were stored at −80°C until
gene expression profiling on Affymetrix U133A gene chips (Santa Clara, CA). The same
array platform, standard operating procedure and normalization method (dCHIP) was used
as previously reported (13). The reference chip and normalization procedure are available
online1. FNA samples contain on average 80% neoplastic cells and little or no normal breast
epithelium or stromal cells (16). Gene expression information generated from FNAs
represents the molecular characteristics of the invasive cancer, including the molecular class
(3). RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA).
The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer
(Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if
the optical density260/280 ratio was ≥1.8 and the total RNA yield was ≥1µg. Seventy-five
percent of all aspirations yielded at least 1 µg total RNA required for the gene expression
profiling. Previously, thirty-one total RNA specimens were split, labeled, and hybridized in
duplicates several months apart in the same and in a different laboratory to assess technical
reproducibility of gene expression–based predictions, and demonstrated 97% concordance in
these replicate experiments (13). Gene expression profiling was performed on Affymetrix
U133A gene chips in batches over a 3 year period at MD Anderson Cancer Center. Genomic
prediction of response was performed using a standardized computer code (13,17).
Expression results from the thirty selected predictor genes were entered into the class
prediction algorithm and each case was assigned a response status of “pCR” or “residual
disease (RD)” prospectively, before actual pathologic outcome data became available. The
complete microarray data of this trial is available at the GEO database accession number
GSE20271.
We also evaluated the predictive performance of a previously established multivariate
clinical nomogram that is freely available online2 (14). This nomogram combines
information from patient age, tumor size, histologic grade and estrogen receptor status to
predict probability of pCR after preoperative T/FAC or FAC chemotherapies. None of the
current cases were included in the development of the genomic or clinical response
predictors.
Predictive performances are presented as sensitivity, specificity, positive and negative
predictive values and area under the receiver operating characteristic (ROC) curve (AUC).
For the clinical nomogram, we also report calibration (i.e., agreement between observed
outcome frequencies and predicted probabilities) and discrimination (i.e., whether the
relative ranking of individual predictions is in the correct order).
1http://www.bioinformatics.mdanderson.org/pubdata.html
2www.mdanderson.org/pcr
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Statistical design
The primary objective of this study was to establish that patients with DLDA-30-positve
tumors are significantly more likely to experience pCR to T/FAC chemotherapy than
patients who are predicted to have residual cancer by the genomic predictor. The secondary
objectives of the study were to compare the pCR rates between the sequential T/FAC and
FAC×6 treatment arms, and to assess interaction between prediction status assigned by the
DLDA-30 predictor and pCR to two different neoadjuvant chemotherapies. The primary
endpoint of this study was to assess the rate of pCR after completion of preoperative
chemotherapy. Sample size was calculated based on the primary objective using computer
simulations. Computer simulations were carried out to estimate the power to detect gene
expression profile effects and profile-by-treatment interaction effects at different sample
sizes. The following assumptions were used based on the original discovery and validation
results (13): (i) the prevalence of DLDA-30 marker-positive patients is 30% (since the pCR
rate after T/FAC is expected to be approximately 25–30% in unselected patients), (ii) pCR
rate to T/FAC treatment in the marker-positive group is ≥ 60% (based on the positive
predictive value observed in the previous single arm study) (13), and (iii) pCR rate to FAC
treatment in the marker-positive group is between 20–40% (higher than 10–15% seen
historically in unselected patients but lower than observed for T/FAC). Repeated fitting of a
logistic regression model with 10,000 iterations for each case were performed with pCR as
the dependent variable and including terms for treatment, microarray profile group, and
treatment-profile interaction. With these assumptions, a study with 210 patient (105 in each
arm) would have a ≥95% power to detect a significant marker effect for T/FAC therapy (i.e.
significantly higher pCR rates in marker-positive compared to marker-negative cases).
However, with this sample size the power varies substantially to detect significant marker-
treatment arm interaction effect depending on differences in pCR rates between the
treatment arms (Supplementary Table 1). We assumed a 25–30% loss of samples and
therefore the maximum sample size was set to 273. In the final analysis we used multivariate
logistic regression models with terms for age, treatment, tumor size, grade, ER and HER-2
status and genomic prediction to calculate odds ratios for pCR.
In a hypothesis-generating, exploratory analysis we searched for novel differentially
predictive genes by fitting logistic regression models with response (pCR vs. RD) as the
outcome and with treatment type (FAC vs. TFAC) and gene expression values of gene i (for
each probe set on the U133A chip) as covariates. We included a test for interaction between
treatment and gene expression, and calculated the p-value for the gene-treatment interaction
term. To adjust for multiple testing, we used a beta-uniform mixture (BUM) model to
estimate the false discovery rate (FDR) (18). In order to explore the power of the interaction
test in the completed study, we generated 4 random normal distributions representing
particular gene expression values - one for each treatment-response group. The values for
the means and standard deviations were taken from the observed normalized and log2
transformed microarray data. Each distribution had standard deviation = 0.3 and sample size
equal to that from the data (pCR/FAC: n=7, RD/FAC: n=80, pCR/TFAC: n=19, RD/TFAC:
n=72), we set the means for pCR/FAC and RD/FAC to 2.5 (i.e. no effect on FAC response
by gene expression), we also set the mean for RD/TFAC to 2.5 and varied the mean for
pCR/TFAC from 2.5 to 3.2. We fit the logistic regression model described above. Over 50
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iterations, we tracked how often the interaction test p-value was <0.05 for a given gene and
took this value as the measure of the power of the test. When the pCR/TFAC mean was 2.6
the power was 14%. For 2.7, the power was 30%; for 2.8, the power was 51%; for 2.9, the
power was 72%; for 3.0, the power was 86%; for 3.1, the power was 92%; and for 3.2, the
power of the interaction test was 98%.
RESULTS
Patient characteristics and response to chemotherapy
Two hundred and seventy three patients were enrolled, 138 were randomized to T/FAC and
135 to FAC chemotherapy (intent-to-treat population). Twenty (7%) and 16 (6%) patients
were excluded from genomic response analysis in each treatment arm respectively due to
eligibility violations including non-study treatment regimen, patient withdrawal or lack of
pathologic assessment of response. Of the 118 patients who received T/FAC, 9 patients
progressed clinically, these were considered as residual disease for response prediction
analysis. Of the 119 patients who were assigned to receive FAC chemotherapy, 11 received
T/FAC treatment (to maximize response or due to progression on FAC) and these cases
were assigned to the T/FAC treatment group for genomic response prediction analysis. The
remaining 108 cases, including 5 cases that progressed, comprised the FAC treatment cohort
for the final response prediction analysis (Supplementary Table 2). Figure 1 illustrates the
flow and assignment of specimens.
Based on treatment received, the pCR rates were significantly higher 19% (n=24/129) in the
T/FAC arm compared to 9% (n=10/113) in the FAC arm (p<0.05). For the calculation of
FAC efficacy, the 5 cases that were resistant to FAC and were crossed over to the T/FAC
arm were counted as FAC failures, thus n=108+5=113. In the intent-to-treat population, the
pCR rates were the same as above, 19.6% (n=27/138) and 9.6% (n=13/135) in the T/FAC
and FAC arms (p<0.05), respectively.
Two hundred and four FNA samples (75%) yielded sufficient quality and quantity of RNA
to perform gene expression analysis. The main reasons for failure were acellular aspirates
and low RNA yield; 5 profiles (2.5%) failed array QC after hybridization. After excluding
the patients who had no response information available (Figure 1), 178 cases remained with
complete pathologic response and genomic prediction results for final analysis. Of these, 91
received T/FAC and 87 received FAC chemotherapy. Clinical characteristics of these
patients are presented in Table 1. Both treatment groups were well balanced for age, race,
histological type and grade, tumor size, clinical nodal status, and hormone receptor and
HER2 status. The pCR rates were 21% (95%CI:0.13–0.29) in the T/FAC group (n=19) and
8% (95%CI:0.02–0.14) in the FAC group (n=7) (p=0.019).
Performance of the DLDA-30 genomic predictor and the clinical nomogram to predict pCR
In the T/FAC arm, the positive predictive value (PPV) of the genomic predictor was 38%
(95%CI:21–56%), the negative predictive value (NPV) was 88% (CI:77–95%), sensitivity
and specificity were 63% (CI:38–84%) and 72% (CI:60–82%), respectively. The observed
pCR rate was 38% in the cohort that was predicted to achieve pCR (marker-positive
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patients), compared to 19% in unselected patients (p=0.032), and 12% in the marker-
negative patients (patients predicted to have residual disease) (p=0.006). The AUC was
0.711 (CI:0.570–0.852). In the FAC-only arm, the PPV and NPV were 9% (CI:1–29%), and
92% (CI:83–97%), respectively. The sensitivity and specificity were 29% (CI:4–71%) and
75% (CI:64–84%), and the AUC was 0.584 (CI:0.353–0.815) (Figure 2A and Table 2). The
observed pCR rates were identical (9%) in the overall population and in the marker-positive
and -negative patient subsets.
We applied the clinical nomogram to the same 178 patients for which microarray-based
prediction was available (Figure 2B and Table 2). In the T/FAC arm, the discrimination was
high with an AUC of 0.89 (95%CI:0.85–0.93), which was not statistically significantly
different from the AUC of the DLDA-30 predictor. The model was also well calibrated with
no significant difference between the predicted and the observed probability (p=0.21). When
the nomogram was applied to patients who received FAC, the discrimination remained high
with an AUC of 0.82 (95%CI: 0.75–0.89), but the calibration was less good, the nomogram
significantly (p=0.03) over-predicted pCR. Thus, the clinical predictor was accurate in
predicting pCR after T/FAC, and less accurate but still effective in predicting pCR after
FAC×6.
Multivariate logistic regression model
In a multivariate analysis using all samples (n= 178) and including treatment arm, age,
clinical tumor size, clinical nodal status, grade, ER and HER2 status, and DLDA-30 score as
variables, only ER status (p=0.008), tumor size (p=0.018), and treatment arm (p=0.015)
were significant independent predictors of pCR. In the T/FAC treatment cohort, only ER
status (p=0.022) and tumor size (p=0.046) were independent predictors of pCR. In the FAC
treatment cohort, none of the variables was a significant predictor for pCR. The small
number of events (seven pCR) and lack of power may have prevented the identification of
any significant predictors with confidence within this subset.
New candidate biomarker identification using marker-treatment interaction test
In an exploratory analysis, we examined what genes were differentially predictive of
response (pCR vs RD) by treatment arm by testing for gene-treatment interaction. When all
probe sets on the U133A microarray were considered individually, logistic regression
models identified 206 probe sets with interaction p values ≤0.05 (Supplementary Table 3).
The gene with the most significant gene expression-treatment interaction p-value was the
inositol polyphosphate-5-phosphatase (INPP5A) (Figure 3). After adjustment for multiple
comparisons using the beta uniform mixture model of p-values, no probe sets remained
significant at a reasonable false detection rate (FDR). The p-value distribution showed a
paucity of low p-values indicating a lack of power for the individual comparisons.
Supplementary Table 4 contains the gene-treatment interaction results for the individual 30
probe sets included in the DLDA-30 predictor. The overall DLDA-30 score showed no
significant interaction with treatment (p=0.443). Three of the individual probe sets including
Na+/K+ transporting ATPase interacting protein 1 (NKAIN1), meteorin (METRN), and
delta 2 catenin (CTNND2) showed significant interaction with treatment (p≤0.05), and one
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probe set (G protein-coupled receptor activity modifying protein 1, RAMP1) had borderline
significance (p=0.051). Figure 4 shows the plots of the fitted logistic regression models for
the 4 genes and for the overall score. The plots show how the probability of pCR varies by
treatment arm as a function of gene expression level or DLDA-30 score values.
Retrospective power calculations for interaction test based on mean gene expression values
for the DLDA-30 probe sets and observed response rates using logistic regression model,
indicated that the current study had a power between 14%–50% to detect significant
interaction effects.
DISCUSSION
We tested a multigene predictor of pCR to preoperative sequential weekly paclitaxel and
FAC chemotherapy from fine-needle biopsies of breast cancers in a prospective randomized
international trial. pCR is important as a clinical end point because these patients experience
excellent cancer-free long-term survival.
The 30-gene predictor was predictive of response to T/FAC chemotherapy. Patients who
were predicted to achieve pCR to T/FAC (marker-positive patients) had significantly higher
pCR rates (38%, 95%CI:21–56%) than unselected patients (19%, p=0.032), or patients
predicted to have residual disease (12%, p=0.006) (marker-negative patients) when treated
with this regimen. These results confirm that the multigene predictor can identify patients
with greater than average sensitivity to T/FAC chemotherapy; they are consistent with two
previous small studies (13,17).
A test that could be used to select one therapy over another needs to have a high positive
predictive value and high sensitivity. Our test achieved a PPV of 38%, a sensitivity of 63%
and the negative predictive value (NPV) was 88%. These performance measures were less
than what we have observed in the earlier validation studies but were still within the 95%
confidence intervals of the earlier performance estimates. Therefore, these results are
consistent with the previous reports (13,17).
It is increasingly clear that general chemotherapy sensitivity can also be gauged by
considering routine clinical variables such as proliferative activity, ER and HER-2 status,
molecular subtype and histologic grade. Basal-like (or triple-negative) breast cancers have
higher likelihood of pCR after preoperative chemotherapy than other molecular subtypes,
and among the ER-positive cancers, high Oncotype DX recurrence score, Luminal-B
molecular class, HER-2 overexpression and high genomic grade are each associated with
greater chemotherapy sensitivity (3–7). All these assays tend to capture molecular
characteristics of similar patients with clinically ER-negative, and/or high grade and high
proliferation tumors. When we compared the predictive performance of the DLDA-30
genomic test in T/FAC treated patients with a multivariate clinical prediction model
including grade and ER status, the overall predictive performance of the genomic test was
similar to the performance of the clinical nomogram. In a multivariate logistic regression
analysis that included all patients, only ER-status, tumor size and treatment arm but not the
genomic test results were independent predictors of pCR. This indicates that this first
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generation genomic chemotherapy response predictor mostly captures gene expression
information associated with clinical phenotype, particularly ER status and proliferative
activity that is reflected in histological grade. This study illustrates an inherent pitfall in
developing predictive markers from patient cohorts that include different breast cancer
subtypes. Estrogen receptor-positive and -negative cancers have large-scale gene expression
differences, and they also have substantially different sensitivities to preoperative
chemotherapy and this can lead to confounding of estrogen regulated genes with treatment
response genes in studies that consider all breast cancers together. During the development
of the DLDA-30 predictor cases with pCR were compared to cases with residual cancer and
both ER-positive and -negative cancers were included in the analysis. Inevitably the
predictor included many genes that reflected the phenotypic differences between responders
(pCR) and non-responders (RD), responders being predominantly triple-negative cancers
and highly proliferative ER+ cancers. To illustrate this point we tested the DLDA-30 pCR
predictor as a predictor of ER-status: in the current study population it had a PPV of 0.7 and
AUC of 0.766 as predictor of ER-negative versus -positive phenotype. Similar phenotype-
associated predictive value limits the use of the 70-gene prognostic signature (MammaPrint)
or OncotypeDx in ER-negative breast cancers (19). The next generation predictive (and
prognostic) markers will need to be developed separately for different molecular subsets of
breast cancers in order to increase their clinical utility (20).
A secondary objective of this randomized study was to evaluate the regimen specificity of
the DLDA-30 predictor by assessing its performance on the FAC-treated patients. Excellent
survival in patients who achieve pCR most likely reflects benefit from chemotherapy since
most clinical and molecular characteristics associated with pCR (ie, ER-negative status, high
histologic or genomic grade, high Oncotype DX recurrence score, basal-like or Luminal-B
molecular class “intrinsic subtype”) predict worse natural history in the absence of
chemotherapy (5,6,7). But the above variables predict general chemosensitivity of a tumor,
which can be useful clinically. However more useful will be the predictive test that can
discriminate between the probability of response to different chemotherapies and thus help
guide the rational selection of specific treatment in individual patients. We tested the
performance of the genomic predictor in the two treatment arms. The DLDA-30 identified a
patient population that is more likely to achieve pCR after T/FAC chemotherapy than the
general patient population, but it did not predict pCR in the FAC-only treatment arm. In that
arm the PPV and NPV were 9% and 92% respectively and the sensitivity and specificity
were 29% and 75% with an AUC of 0.584. This indicates that our genomic predictor may
have some-regimen specificity. Alternatively, this may also represent a false-negative
finding due to lack of power because of the small number of events in the FAC group (pCR
n=7) and small overall sample size. The marker-treatment interaction test was also not
significant, but post hoc power calculations showed 14–50% power to detect significant
interaction effects for individual probe sets or for the combined DLDA-30 score.
Interestingly, although the genomic predictor performed similarly to the clinical pCR
predictor nomogram at predicting response to T/FAC, the clinical nomogram retained a
comparable predictive accuracy in FAC-treated patients while the genomic test did not. This
further supports some degree of regimen specific predictive value for the genomic test that
the clinical predictor lacks.
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The ideal data to develop treatment specific predictors is a randomized trial that is
adequately powered to identify individual genes with significant treatment-marker
interaction effect. However, such data sets are rare and prospective power calculations for
gene-treatment interaction tests are difficult because the magnitude of effect is unknown and
it is likely to be variable for different genes. The current data set provided an opportunity to
perform an exploratory analysis. We examined each probe set on the array for potential
marker-treatment interaction effect. This analysis was undertaken to assess if we could
identify genes that have larger gene-treatment-response interaction effect than the probes
sets that were included in the DLDA-30 predictor. We identified numerous, potential
treatment-arm specific predictor candidates (Supplementary Table 3). These genes will need
to be tested in other independent data sets.
We also show that weekly paclitaxel × 12 followed by FAC × 4 regimen results in
significantly higher pCR rate (19% versus 9%, p<0.05) than 6 courses of FAC (or FEC).
The pCR rates for T/FAC are consistent with findings from a larger study using the same
preoperative therapy (21). These results support the increasing consensus that the addition of
a taxane to anthracycline-based therapy improves pCR rates and long-term outcomes in
breast cancer.
In summary, prospective gene expression analysis for response prediction was feasible in
this randomized, international trial. Seventy-five percent of the FNA specimens mailed to a
central laboratory yielded adequate RNA for genomic analysis. A 30-gene molecular test
was predictive of pCR to T/FAC and not to FAC chemotherapy, but it did not perform better
than a freely available web-based clinical nomogram. The clinical nomogram, however,
lacked regimen-specificity and predicted response equally well to both T/FAC and FAC.
Like most other currently in use molecular response predictors, that rely on measuring
molecular equivalents of clinical phenotype, this first generation genomic predictor derives
its predictive value from detecting the large-scale gene expression differences that
distinguish ER-negative from ER-positive tumors and high grade from low grade cancers.
To improve their clinical utility, second generation genomic predictors will need to be
developed separately for the different molecular and phenotypic subsets of breast cancers.
TRANSLATIONAL RELEVANCE
There are several clinical and molecular features that can identify generally more or less
chemotherapy sensitive subsets of breast cancers but there are no clinically useful
predictive biomarkers that can guide the selection of one chemotherapy regimen over
another in individual patients. We tested a 30-gene predictor of pathologic complete
response to neoadjuvant sequential weekly paclitaxel and FAC chemotherapy from fine-
needle biopsies of breast cancers in a prospective randomized international trial. We also
compared the treatment efficacy of T/FAC vs FAC×6 chemotherapies. The results
confirm the ability of the genomic predictor to identify patients with higher than average
sensitivity to T/FAC chemotherapy but not to FAC treatment. Prospective gene
expression biomarker analysis was technically and logistically feasible in this multicenter
international trial. Most current molecular response predictors in breast cancer including
this one suffer from capturing molecular equivalents of clinical phenotype. To improve
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their clinical utility, second generation genomic predictors will need to be developed
separately for the different molecular and phenotypic subsets of breast cancers.
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Figure 1. Flow chart of patients and samples used in the analysis
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Figure 2. Receiver operating characteristic (ROC) and calibration curves measure the
performance of the genomic and clinical predictors
(A) ROC curve for the predictive performance of the DLDA-30 genomic pCR predictor on
the 178 cases for whom an observed pathologic tumor response and molecular prediction of
tumor response were available. (B) ROC and calibration curves for the predictive
performance of the clinical nomogram to predict pCR on the same cases used in the genomic
analysis. The corresponding performance metrics of the genomic and clinical predictors are
found in Table 2.
Abbreviations: FAC = 5-Fluorouracil, Doxorubicin and Cyclophosphamide; T/FAC =
weekly Paclitaxel and 5-Fluorouracil, Doxorubicin and Cyclophosphamide; AUC = Area
Under the ROC Curve.
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Figure 3. Expression of the inositol polyphosphate-5-phosphatase (INPP5A) gene in the two
response cohorts within the two treatment arms
INPP5A had the most significant gene expression-treatment arm interaction p-value (p=
0.00193, unadjusted for multiple comparisons). “*” indicates the mean value.
Abbreviations: pCR=pathologic complete response, RD=residual cancer, T/FAC= weekly
Paclitaxel and 5-Fluorouracil, Doxorubicin and Cyclophosphamide, FAC= 5-Fluorouracil,
Doxorubicin and Cyclophosphamide.
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Figure 4. Plots of the fitted logistic regression models illustrating the gene-treatment interactions
for the 4 most significant genes of the DLDA-30 predictor and the 30-gene prediction score itself
The plots show how the probability of pCR varies by treatment arm as function of gene
expression level or DLDA score values.
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Table 2
Performance metrics of the genomic and clinical predictors
The corresponding ROC and calibration curves are represented graphically in Figure 2.
T/FAC (n=91) FACx6 (n=87)
Genomic predictor
ROC AUC 0.711 (95%CI:0.570–0.852) 0.584 (95%CI:0.353–0.815)
PPV 38% (95%CI:21–56) 9% (95%CI:1–29)
NPV 88% (95%CI:77–95) 92% (95%CI:83–97)
Sensitivity 63% (95%CI:38–84) 29% (95%CI:4–71)
Specificity 72% (95%CI:60–82) 75% (95%CI:64–84)
Clinical predictor
Discrimination (ROC) AUC 0.89 (95%CI:0.85–0.93) 0.82 (95%CI:0.75–0.89)
Calibration
p-value 0.21 0.03
E max 10.5% 15.5%
E average 4.8% 9.2%
Abbreviations: FAC = 5-Fluorouracil, Doxorubicin and Cyclophosphamide; T/FAC = weekly Paclitaxel and 5-Fluorouracil, Doxorubicin and
Cyclophosphamide; AUC = Area Under the ROC Curve, ROC = receiver operating characteristic, CI = confidence interval; E = difference in
predicted probabilities and observed frequencies; E max = maximal error, E average= average error.
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